Compare AbbVie Inc (ABBV) vs General Dynamics Corporation (GD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs General Dynamics Corporation — how do they compare? AbbVie Inc trades at $253.82 (market cap $449.91B), while General Dynamics Corporation trades at $372.8 (market cap $101.31B). The key difference: AbbVie Inc is far larger — about 4.4× General Dynamics Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | GD | |
|---|---|---|
Market Cap | $449.91B | $101.31B |
Sector | Health | Industrials |
52-Week High | $261.07 | $376.88 |
52-Week Low | $184.85 | $296.65 |
Enterprise Value | $513.38B | $107.49B |
Dividend Yield | 2.72% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
General Dynamics (GD) trades at $374.64, up 0.29% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, while fundamentals are solid with revenue growth to $52.55 billion in 2025 and net income of $4.21 billion. Recent earnings beats and a massive $130.8 billion backlog support positive momentum, with analyst consensus leaning bullish.
Outlook remains favorable given defense budget tailwinds and execution strength, but valuation multiples like P/E of 23.72 suggest limited upside from current levels. Risks include contract execution delays and macroeconomic pressures. The stock offers steady growth and income via dividends, but investors should weigh rich valuations against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
